Compare Natera Inc. Common Stock (NTRA) vs Trekor Metals Limited Common Shares (TGB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Trekor Metals Limited Common Shares — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Trekor Metals Limited Common Shares trades at $8.2 (market cap $3.00B). The key difference: Natera Inc. Common Stock is far larger — about 19× Trekor Metals Limited Common Shares's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Trekor Metals Limited Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Trekor Metals Limited Common Shares for 4 Days on average.
| NTRA | TGB | |
|---|---|---|
Market Cap | $57.03B | $3.00B |
Volume | 1,131,157 | 2,867,603 |
Sector | Health | Basic Materials |
52-Week High | $425.64 | $9.68 |
52-Week Low | $179.42 | $3.75 |
Typical Hold Time | 0 Days | 4 Days |
Enterprise Value | $56.18B | $3.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
TGB trades at $8.56, down 1.72% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue projected to grow from $673M in 2025 to $985M in 2026, turning from a net loss of $30M to a $16M profit. Recent copper production announcements highlight operational strength, though valuation metrics remain elevated with a P/E of 406.88. Analyst sentiment is mixed with a 25% buy rating amid balanced hold/sell recommendations.
The outlook for TGB hinges on copper production growth from Gibraltar and Florence mines, supporting revenue expansion and margin improvement. Key risks include execution challenges in mine ramp-ups, commodity price volatility, and high debt levels. While technical indicators suggest near-term upside, the stock's rich valuation requires careful monitoring of earnings delivery against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Trekor Metals Limited Common Shares
Trekor Metals is a mining company focused on copper. It operates the Gibraltar Mine and develops projects involving copper, gold, silver, and niobium.
Read more on TGB →
